|

transfusion of 2×10^9 PD-1 edited TILs per kg body weight Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Ruijin Hospital1

Indications

  • PD-11
  • Tumor Infiltrating Lymphocytes1
  • Colorectal Cancer (CRC)1
  • Cancer1

Other1 trial

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.